Vir Biotechnology (NASDAQ: VIR)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Vir Biotechnology Returns vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Vir Biotechnology Company Info
News & Analysis
These growth stocks have substantial tailwinds.
The innovative companies have made great gains in a short period of time.
A COVID-19 partnership with a major drugmaker is producing more fruit than expected.
Joining the S&P SmallCap 600 could boost the company's profile.
The S&P SmallCap 600 index will soon include Vir.
Looking for small healthcare companies with huge revenue opportunities? Try these.
Vir Bio has a COVID blockbuster in Xevudy, and the stock is super-cheap right now.
The immunology specialist says it can help combat omicron.
Motley Fool Returns
Market-beating stocks from our award-winning analyst team.
Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 03/29/2023.
Discounted offers are only available to new members. Stock Advisor list price is $199 per year.
Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.